Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Cash & Equivalents (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Cash & Equivalents for 11 consecutive years, with $155.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Equivalents fell 17.82% to $155.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $155.5 million, a 17.82% decrease, with the full-year FY2025 number at $155.5 million, down 17.82% from a year prior.
  • Cash & Equivalents was $155.5 million for Q4 2025 at Intellia Therapeutics, down from $193.4 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $523.5 million in Q4 2022 to a low of $120.5 million in Q3 2024.
  • A 5-year average of $189.1 million and a median of $155.8 million in 2025 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: crashed 64.09% in 2021, then soared 317.18% in 2022.
  • Intellia Therapeutics' Cash & Equivalents stood at $125.5 million in 2021, then skyrocketed by 317.18% to $523.5 million in 2022, then plummeted by 56.69% to $226.7 million in 2023, then fell by 16.57% to $189.2 million in 2024, then fell by 17.82% to $155.5 million in 2025.
  • Per Business Quant, the three most recent readings for NTLA's Cash & Equivalents are $155.5 million (Q4 2025), $193.4 million (Q3 2025), and $156.2 million (Q2 2025).